NCT06516952

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 330 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Conditions

• Prurigo Nodularis

Interventions

Type	Name	Description
DRUG	Povorcitinib	Oral Tablet
DRUG	Placebo	Oral Tablet

Timeline

• Start date: 2024-10-10
• Primary completion: 2026-10-19
• Completion: 2027-05-03
• First posted: 2024-07-24
• Last updated: 2026-04-13

Locations

120 sites across 12 countries: United States, Argentina, Austria, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, South Korea, Switzerland

Regulatory

• FDA-regulated drug study